Crispr Therapeutics AG Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Orbis Investment Management and Allan Gray Australia report a combined 5.6% beneficial ownership in CRISPR Therapeutics AG.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7,987,262 shares, representing 8.3% of the outstanding common stock of CRISPR Therapeutics AG.
NASDAQ
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report a combined 6.3% stake in CRISPR Therapeutics AG as of March 31, 2026.
NASDAQ
Capital World Investors has disclosed a beneficial ownership of 5.1% in CRISPR Therapeutics AG, holding 4,929,428 shares.
NASDAQ
ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting beneficial ownership of 11.79% of CRISPR Therapeutics AG's common stock as of March 31, 2026.
NASDAQ
Orbis Investment Management Ltd. and Allan Gray Australia Pty Ltd. have disclosed a combined 6.2% beneficial ownership stake in CRISPR Therapeutics AG common stock.
NASDAQ
Capital International Investors has filed an amended Schedule 13G, reporting a passive 1.2% beneficial ownership stake in CRISPR Therapeutics AG.
NASDAQ
Orbis Investment Management and Allan Gray Australia have jointly disclosed a 5.5% beneficial ownership stake in CRISPR Therapeutics AG common stock.
NASDAQ
ARK Investment Management LLC and Catherine D. Wood have reported an aggregate beneficial ownership of 10.76% in CRISPR Therapeutics AG common stock.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a 6.9% beneficial ownership stake in CRISPR Therapeutics AG as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: ARK Investment Management and Catherine Wood Disclose 11.85% Stake in CRISPR Therapeutics AG
ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 11 to Schedule 13G, disclosing a combined beneficial ownership of 11.85% in CRISPR Therapeutics AG as of March 31, 2025.
NASDAQ
Capital International Investors has filed an amended Schedule 13G, reporting a 7.4% beneficial ownership stake in CRISPR Therapeutics AG as of March 31, 2025.
NASDAQ
ARK Investment Management LLC has filed an amended Schedule 13G, revealing a 10.51% beneficial ownership stake in CRISPR Therapeutics AG as of December 31, 2024.
NASDAQ
ARK Investment Management LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 8.80% in CRISPR Therapeutics AG as of September 30, 2024.